...
首页> 外文期刊>Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association - European Renal Association >Up-regulation of TRAIL mRNA expression in peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome.
【24h】

Up-regulation of TRAIL mRNA expression in peripheral blood mononuclear cells from patients with minimal-change nephrotic syndrome.

机译:微小变化性肾病综合征患者外周血单个核细胞中TRAIL mRNA表达的上调。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Minimal-change nephrotic syndrome (MCNS) is considered to be associated with T-cell dysfunction and with the abnormal secretion of putative glomerular permeability factors; however, the nature of such factors remains elusive. METHODS: To identify up-regulated genes during the nephrosis phase, we undertook serial analyses of gene expression (SAGE) in peripheral blood mononuclear cells (PBMC) from a patient with MCNS sampled during the nephrosis and remission phases. To confirm the SAGE results, we performed quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR) analyses. We also measured the serum levels of the identified gene product in nephrosis and remission samples from 29 MCNS patients, 57 patients with nephrotic syndrome due to other types of glomerular diseases and 30 healthy individuals. RESULTS: Using more than 20,000 SAGE tags, we identified 15 functionally known genes that were up-regulated (>or=4-fold) in PBMC from the MCNS patient during the nephrosis phase. For further examination, we selected two genes encoding secretory proteins, namely tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) and tissue inhibitor of metalloprotease 1. Real-time RT-PCR analysis confirmed a higher expression of TRAIL mRNA in PBMC during nephrosis than during remission in eight MCNS patients. The expression pattern of TRAIL mRNA, however, was variable among four patients with membranous nephropathy. There was no significant increase of serum levels of a soluble form of TRAIL in MCNS patients during the nephrosis phase. CONCLUSIONS: These results suggest that the intracellular TRAIL mRNA expression in PBMC is up-regulated in MCNS patients during the nephrosis phase. This change may represent either an epiphenomenon or it may provide a potential explanation for the altered T-cell function in MCNS.
机译:背景:最小变化型肾病综合征(MCNS)被认为与T细胞功能障碍和推测的肾小球通透性因子异常分泌有关。但是,这些因素的性质仍然难以捉摸。方法:为了鉴定在肾病阶段的上调基因,我们对来自肾病和缓解阶段的MCNS患者的外周血单个核细胞(PBMC)中的基因表达(SAGE)进行了系列分析。为了确认SAGE结果,我们进行了定量实时逆转录聚合酶链反应(RT-PCR)分析。我们还测量了来自29位MCNS患者,57位因其他类型的肾小球疾病导致的肾病综合征患者和30位健康个体的肾病和缓解样本中已鉴定基因产物的血清水平。结果:使用超过20,000个SAGE标签,我们鉴定了15个功能已知的基因,这些基因在肾病期的MCNS患者的PBMC中被上调(≥4倍)​​。为了进一步检查,我们选择了两种编码分泌蛋白的基因,即肿瘤坏死因子相关的凋亡诱导配体(TRAIL)和金属蛋白酶1的组织抑制剂。实时RT-PCR分析证实,肾病期间PBMC中TRAIL mRNA的表达更高比八名MCNS患者的缓解期间要好但是,在四名膜性肾病患者中,TRAIL mRNA的表达模式是可变的。在肾病期,MCNS患者的可溶形式TRAIL血清水平没有显着增加。结论:这些结果表明在肾病期MCNS患者中PBMC中细胞内TRAIL mRNA表达上调。这种变化可能代表一种现象,也可能为MCNS中T细胞功能的改变提供潜在的解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号